Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7401 - 7408 of 12142 results
Software is Still Patent Eligible
February 16, 2017| Advisory| Viewpoint
Portman-Shaheen Energy Efficiency Bill Reintroduced in Senate
February 15, 2017| Blog| Viewpoint
CMS’s Draft 2018 Call Letter: Minor Updates, but Largely a Continuation of Current Policies
February 15, 2017| Blog| Viewpoint
Tax Guidance to Slow Under Trump. Even More Emphasis on Letter Rulings in Bond Transactions?
February 15, 2017| Blog| Viewpoint
Supreme Court Delays Oral Arguments Regarding Employment ‘Class Arbitration’ Waivers
February 14, 2017| Blog| Viewpoint
WEBINAR – Access, Correction, Erasure and Portability under the GDPR: How to Minimize the Burden
February 14, 2017| Blog| Viewpoint
Another Court Agrees That A Difference Of Opinion On Medical Necessity Is Insufficient to Show Falsity Under the False Claims Act
February 14, 2017| Blog| Viewpoint
Update: Administration’s Possible Next Steps on the Travel Ban
February 14, 2017| Alert| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts
Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|